Phase III

Serum neurofilament light: A biomarker for disease activity in MS
1920 1080 Mea Holm, PhD

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

read more
  • Mea Holm, PhD
  • 0
  • 0

Quarterly migraine injection approved in US
2885 1900 Peter Stevenson, PhD

The US FDA has approved a new humanised monoclonal antibody for migraine prevention in adults. Fremanezumab-vfrm – under the brand name AJOVYTM (Teva Pharmaceuticals) – prevents the interaction between calcitonin…

read more
  • Peter Stevenson, PhD
  • 1
  • 0

FDA approves blockbuster migraine treatment
1200 800 Mea Holm, PhD

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…

read more
  • Mea Holm, PhD
  • 1
  • 0

First MS treatment approved for children & adolescents
1600 1067 Peter Stevenson, PhD

The US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10 to 18 years with relapsing…

read more
  • Peter Stevenson, PhD
  • 0
  • 0

Solriamfetol improves wakefulness in narcolepsy patients
1920 1280 Lutz Achtnichts, MD

This year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment of excessive sleepiness (ES) in…

read more
  • Lutz Achtnichts, MD
  • 0
  • 1

​Promising new migraine treatment presented at AAN 2018
5184 3456 Lutz Achtnichts, MD

Migraine is consistently ranked among the top 20 most burdensome diseases worldwide. Until now, existing prophylactic therapies for episodic migraine consisted mostly of repurposed medications for other conditions. They are…

read more
  • Lutz Achtnichts, MD
  • 0
  • 2

ECTRIMS-ACTRIMS: A conversation with Prof. Till Sprenger
150 150 Lutz Achtnichts, MD

I had the chance to meet up with Professor Sprenger at ECTRIMS-ACTRIMS in Paris last week. We discussed the TEMSO study, which has been evaluating the long-term treatment effect of teriflunomide…

read more
  • Lutz Achtnichts, MD
  • 0
  • 0

ECTRIMS-ACTRIMS: Phase III data EXPAND on siponimod for secondary progressive multiple sclerosis
898 506 Peter Stevenson, PhD

Data presented at the recent 7th joint ECTRIMS-ACTRIMS meeting in Paris delved deeper into the efficacy of siponimod in the treatment of secondary progressive MS (SPMS). As Robert Fox (Mellen…

read more
  • Peter Stevenson, PhD
  • 0
  • 0
welcome-to-brainwork-ectrims-2017

ECTRIMS-ACTRIMS: OBOE study explores biomarkers of neurodegeneration and inflammation in multiple sclerosis
1920 1080 Peter Stevenson, PhD

The development and characterisation of biomarkers in multiple sclerosis (MS) could be a crucial step in understanding disease pathways, as well as the therapeutic mechanisms of disease-modifying treatments. So was…

read more
  • Peter Stevenson, PhD
  • 0
  • 0
Brainwork-NavigateESUS

​NAVIGATE ESUS: Rivaroxaban vs aspirin study terminated due to comparable efficacy
2992 2000 Peter Stevenson, PhD

Early discontinuation has been announced for the Phase III NAVIGATE ESUS study – led by Bayer AG and its development partner Janssen Research & Development, LLC – which had been…

read more
  • Peter Stevenson, PhD
  • 0
  • 0
Brainwork is supported by unrestricted grants from:
This site uses cookies. By continuing to browse this site you are agreeing to our privacy policy & cookies policy.